Schellings, MWM;Baumann, M;van Leeuwen, REW;Duisters, RFJJ;Janssen, SHP;Schroen, B;Peutz-Kootstra, CJ;Heymans, S;Pinto, YMImatinib attenuates end-organ damage in hypertensive homozygous TGR(mRen2)27 rats.Hypertension2006473467-74
Baumann, M;van den Born, BJTreating prehypertensionN Engl J Med20063554417-417
Schalkwijk, CG;Baumann, M;Scheijen, J;Stehouwer, CDAN-epsilon-(carboxymethyl)lysine is increased in plasma and the kidney of spontaneously hypertensive rats and is reduced by losartan and spironolactone, but not by hydralazineDiabetologia200649 Suppl.689-689
Fekete, A;Viklický, O;Hubacek, JA;Rusai, K;Erdei, G;Treszl, A;Vítko, S;Tulassay, T;Heemann, U;Reusz, G;Szabo, AJAssociation between heat shock protein 70s and toll-like receptor polymorphisms with long-term renal allograft survival.Transpl Int2006193190-6
Turk, T;Pietruck, F;Dolff, S;Kribben, A;Janssen, OE;Mann, K;Philipp, T;Heemann, U;Witzke, ORepaglinide in the management of new-onset diabetes mellitus after renal transplantation.Am J Transplant200664842-6
Kohnle, M;Pietruck, F;Kribben, A;Philipp, T;Heemann, U;Witzke, OEzetimibe for the treatment of uncontrolled hypercholesterolemia in patients with high-dose statin therapy after renal transplantation.Am J Transplant200661205-8
Lutz, J;Risch, K;Liu, S;Antus, B;Schmaderer, C;Roos, M;Ouyang, N;Lehmann, M;Heemann, UAngiotensin type 1 and type 2 receptor blockade in chronic allograft nephropathy.Kidney Int20067061080-8
Patschan, D;Kribben, A;Pietruck, F;Lutz, J;Binek, M;Philipp, T;Heemann, U;Witzke, OOKT3 therapy in addition to tacrolimus is associated with improved long-term function in patients with steroid refractory renal allograft rejection.Nephron Clin Pract20061033c94-9
Berthele, A;Hahntow, I;Sprenger, T;Lutz, J;Heemann, U;Conrad, BStabilsation of myasthenia gravis following plasma exchange: combined treatment with rituximab and mycophenolate mofetilJ Neurol2006253 Suppl.106-106
Eyer, F;Pfab, R;Felgenhauer, N;Lutz, J;Heemann, U;Steimer, W;Zondler, S;Fichtl, B;Zilker, TLithium poisoning: pharmacokinetics and clearance during different therapeutic measures.J Clin Psychopharmacol2006263325-30